AlzeCure Pharma: Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856

AI Briefing

• – AlzeCure Pharma's Phase Ib Clinical Study with NeuroRestore ACD856 has completed, marking a significant milestone in the development of its treatment for Alzheimer's disease.
• – The successful completion of the study demonstrates the safety and efficacy of NeuroRestore ACD856 in human subjects.
• – The next steps will focus on further clinical trials to expand the study's results and potentially bring the treatment to patients with Alzheimer's disease.